Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Athyrium Capital Management, LP (CIK 1728001) reported $8.7M across 2 reported positions in its SEC 13F filing for 2024-09-30. Largest positions: BIOR ($5.5M, 63.12%), PBYI ($3.2M, 36.88%), CHRS ($0, 0.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | BIOR | Biora Therapeutics Inc. | $5.5M | 63.12% | 10.9M | Hold |
| 2 | PBYI | PUMA BIOTECHNOLOGY INC | $3.2M | 36.88% | 1.3M | Hold |
| 3 | CHRS | COHERUS BIOSCIENCES INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2024-09-30